Taking a break from prostate cancer treatment

By Lesley Dobson , Monday 10 September 2012

A new way of giving existing prostate cancer treatment can reduce side effects and improve quality of life.
Medical researchMedical research

A new study into treatment for prostate cancer has some promising news for men affected by this condition. The findings have shown that changing the way one treatment is given doesn’t affect survival, and helps patients by reducing side effects.

The UK section of this international trial was funded by Cancer Research UK and led by The Institute of Cancer Research, London. This phase 3 trial involved almost 1,400 men who had already received radiotherapy treatment, which had failed to clear their cancer.

The patients were divided into two groups. One group received an existing hormone therapy drug continuously, which is the standard current treatment. The other group was given the same hormone therapy drug, but treatment was stopped after eight months. This group’s doctors checked their prostate specific antigen (PSA) levels every two months. (PSA is a protein. If you have high levels of PSA it can mean that you have cancer if you haven’t already been diagnosed. In this case the PSA test indicated whether the hormone treatment needed to be re-started.) The men in the study were followed up for an average of around seven years.

When a patient’s PSA level reached a certain level (10 ng per millilitre), their hormone treatment began again, for another eight months. This cycle of eight-monthly treatment interspersed with breaks continued until the end of the treatment.

The results from this trial showed that taking hormone therapy intermittently, rather than continuously, didn’t make a difference to the patients’ length of survival. However, the study did show potential benefits when it came to side effects. The group that received intermittent treatment reported fewer urinary problems and hot flushes, improved sex drive and ability to have an erection.

UK chief investigator Professor David Dearnaley, professor of uro-oncology at The Institute of Cancer Research and honorary consultant at The Royal Marsden NHS Foundation Trust, said: “This large-scale trial has shown that periodically stopping men’s hormone therapy can give them fewer side-effects without reducing their clinical survival, and should lead to a change in clinical practice.

“More than 10,000 men are treated with potentially curative radiotherapy for prostate cancer each year in the UK and so our findings have the potential to benefit thousands of men.

"It would be possible for specialist oncologists and urologists to implement this treatment strategy straight away for individual patients.  Many oncologists, in fact, will have been using this approach already. 

“The monitoring of the intermittent or ‘stop-start’ approach is a little more complicated than the more standard method of continuous hormone therapy with androgen suppression which, in many instances, will be monitored by general practitioners. Monitoring using continuous hormone therapy is quite simple and based on PSA levels (which should be low) and clinical symptoms.  Referral back to a specialist is only required if the PSA level rises.

“In practice, the ‘stop-start’ approach may be more difficult for many General Practitioners to manage.  This has the implication that more patients would need to be followed by specialist oncologists and urologists which would alter the patterns of care and 'patient pathways' in many areas.”  Professor Dearnaly pointed out that any savings from the reduced use of hormone therapy (which costs approximately £100/month) would need to be balanced against the increased cost of more frequent specialist monitoring when using the intermittent ‘stop-start’ approach. 

“It is very important to manage men with prostate cancer recurrence of this type on an individual basis,” added Professor Dearnaly. “For those who have significantly troublesome symptoms from hormonal therapy, the intermittent approach will be very attractive.  Many men, however, have very little in the way of side effects from androgen suppression (hormone therapy), and for these individuals intermittent therapy may offer very little advantage and such men may prefer the easier monitoring with a continuous treatment approach.”

“Results such as these highlight the value of clinical trials,” says Kate Law, Cancer Research UK’s director of clinical research. “Refining treatment to reduce side-effects and improve the outcome for patients remains the key goal. And being able to reduce the side-effects of prostate cancer treatments from currently available treatments offers patients and their doctors the potential of a new option of how their treatment is delivered.”

Useful websites

Cancer Research UK - www.cancerresearchuk.org

NHS Choices - www.nhs.uk

Prostate Cancer UK - http://prostatecanceruk.org

The opinions expressed are those of the author and are not held by Saga unless specifically stated.

The material is for general information only and does not constitute investment, tax, legal, medical or other form of advice. You should not rely on this information to make (or refrain from making) any decisions. Always obtain independent, professional advice for your own particular situation.


  • Tomatoes

    Prostate cancer myths: busted

    Many common beliefs on how to prevent prostate cancer have no basis in fact

    Read on

  • Medical research

    PSA tests: do they save lives or not?

    While a raised PSA level may indicate that a man has prostate cancer, it is not conclusive so can result in unnecessary treatment

    Read on

  • Tablets

    New drug slows prostate cancer growth

    Positive news for men with prostate cancer as a new medication is found to be effective at increasing length and quality of life

    Read on

  • Prostate cancer slide

    Prostate cancer treatment cuts side effects

    Ultrasound can treat prostate tumours with a much lower risk of incontinence and erectile dysfunction

    Read on

  • Prostate cancer ribbon

    New approach could work for prostate cancer

    Starving prostate cancer cells could be effective and avoid unpleasant side effects

    Read on

  • Research

    Prostate cancer: weighing the options

    Prostate cancer is one of the most common cancers - 36,000 men are diagnosed in the UK each year - but unlike many other types of cancer, treatment depends on how fast - or slow-growing - the tumour is, writes Siski Green

    Read on

  • Cancer

    Prostate cancer’s toughest test yet?

    A new approach may help to improve the accuracy of tests for the number one cancer in men.

    Read on

  • Researcher

    Prostate research news

    Just six months of hormone therapy used in combination with radiotherapy can double survival rates of prostate cancer patients, when compared to those who receive only radiotherapy, according to new findings from a University of Newcastle study.

    Read on

  • Health Club

    Health Club

    Free membership and free online assessment to see how healthy you could be.


  • Saga Health Insurance

    Health insurance

    A comprehensive range of competitively priced HealthPlans. 3 months free when you pay by monthly Direct Debit.



Type your comment here

 characters remaining.

Saga Magazine

For more fascinating stories and insightful articles, why not try Saga Magazine for just £1 for 3 issues.

Financial Planning

Financial Planning

The Saga Financial Planning Service provided by my wealth, offers you a simple and straightforward way of ensuring your savings and investments are working hard to achieve your financial objectives.

Saga Magazine app

You can now read your Saga Magazine on a huge range of mobile devices - from the Kindle Fire to an iPhone or iPad.

Fit for life

Saga Magazine's new magbook

All you need to stay fit, healthy and motivated – for just £8.99.